Secor Capital Advisors’s Travere Therapeutics TVTX Stock Holding History

Secor Capital Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-63,966	Closed	-$1.74M	–	571
2018 Q2	$1.74M	Buy	+63,966	New	+$1.7M	0.15%	213
2018 Q1	–	Sell	-88,899	Closed	-$1.87M	–	649
2017 Q4	$1.87M	Buy	88,899 +19,997	+29%	+$457K	0.07%	210
2017 Q3	$1.72M	Buy	68,902 +33,388	+94%	+$735K	0.16%	195
2017 Q2	$689K	Buy	+35,514	New	+$644K	0.06%	312
2017 Q1	–	Sell	-13,941	Closed	-$264K	–	601
2016 Q4	$264K	Buy	+13,941	New	+$285K	0.03%	417

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Secor Capital Advisors's TVTX Position: Q3 2018 in Review

Secor Capital Advisors sold out of Travere Therapeutics (TVTX) in Q3 2018, closing a stake of 63,966 shares — an estimated $1.74M sold.

Secor Capital Advisors first reported a position in TVTX in Q4 2016 and held it in 5 quarters. The position peaked at $1.87M in Q4 2017. 128 funds tracked by Wall St. Rank hold TVTX as of Q3 2018.

Secor Capital Advisors reported no remaining Travere Therapeutics position as of Q3 2018 after selling out during the quarter.
Secor Capital Advisors sold 63,966 Travere Therapeutics shares in Q3 2018, an estimated $1.74M.
Secor Capital Advisors first reported a position in Travere Therapeutics in Q4 2016 and held it in 5 quarters.
Secor Capital Advisors's Travere Therapeutics position peaked at $1.87M in Q4 2017.
128 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2018.

Based on Secor Capital Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.